FDA Approves First-in-Class Drug for Severe Asthma
The US Food and Drug Administration has granted early approval to Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of patients age 12 years and older with severe asthma.
FDA Approvals
source https://www.medscape.com/viewarticle/965139?src=rss
FDA Approvals
source https://www.medscape.com/viewarticle/965139?src=rss
Comments
Post a Comment